Zenas BioPharma (NASDAQ:ZBIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Zenas BioPharma (NASDAQ:ZBIO) from a sell rating to a hold rating in a research report released on Saturday morning.

ZBIO has been the subject of a number of other reports. Morgan Stanley downgraded Zenas BioPharma from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $37.00 to $19.00 in a report on Monday, January 5th. Wedbush reissued an “outperform” rating and set a $45.00 price target on shares of Zenas BioPharma in a report on Monday, December 22nd. Evercore began coverage on shares of Zenas BioPharma in a research report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price target on the stock. Citigroup lifted their price objective on shares of Zenas BioPharma from $27.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Finally, HC Wainwright reissued a “buy” rating and set a $44.00 target price on shares of Zenas BioPharma in a research note on Tuesday, February 10th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.14.

Zenas BioPharma Stock Performance

NASDAQ ZBIO opened at $26.14 on Friday. The stock has a 50-day simple moving average of $26.13 and a two-hundred day simple moving average of $26.17. The firm has a market capitalization of $1.40 billion, a P/E ratio of -3.70 and a beta of -1.47. Zenas BioPharma has a fifty-two week low of $6.11 and a fifty-two week high of $44.60. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66.

Insider Activity at Zenas BioPharma

In related news, CEO Leon O. Moulder, Jr. purchased 57,000 shares of Zenas BioPharma stock in a transaction that occurred on Monday, February 2nd. The stock was purchased at an average cost of $17.96 per share, with a total value of $1,023,720.00. Following the completion of the transaction, the chief executive officer directly owned 423,155 shares in the company, valued at approximately $7,599,863.80. The trade was a 15.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Patricia L. Allen bought 15,700 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average cost of $24.85 per share, with a total value of $390,145.00. Following the completion of the transaction, the director owned 15,700 shares in the company, valued at approximately $390,145. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 202,845 shares of company stock worth $3,747,185 in the last three months. 16.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zenas BioPharma

Several large investors have recently modified their holdings of the stock. Quarry LP raised its stake in shares of Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after buying an additional 291 shares in the last quarter. Deutsche Bank AG boosted its holdings in Zenas BioPharma by 4.5% in the 4th quarter. Deutsche Bank AG now owns 12,781 shares of the company’s stock worth $464,000 after acquiring an additional 554 shares during the period. CWM LLC lifted its stake in shares of Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after acquiring an additional 709 shares in the last quarter. Two Sigma Investments LP raised its stake in shares of Zenas BioPharma by 3.9% in the 3rd quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock valued at $452,000 after purchasing an additional 765 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in Zenas BioPharma by 5.8% in the third quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after purchasing an additional 818 shares during the period.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.